Journal: Cancer immunology research

Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer

doi: 10.1158/2326-6066.CIR-26-0278

Figure Lengend Snippet: (A) Representative IHC staining for PD-L1 of day 18 treated 2153L tumors. Scale bars represent 300μM. Scatter plot of quantification of PD-L1 staining (n=3 mice/group, 5 ROIs/mouse, SEM bars) (B) Violin plot for PD-L1 expression in integrated day 7 PMNC scRNAseq dataset across cell types. One way ANOVA, all p>0.001. (C) Treatment strategy for long term treatment study of CTX + MRX-2843 + aPD1. (D) KM plot of triple combination study. VC n=7, Combo n=11, Triple Combo n=20. (Log-rank test, p value = 0.024, p value < 0.001) (E) Immunofluorescent staining of non-tumor bearing, untreated mammary lymph node compared to long-term responding mice mammary lymph nodes. Dapi (nuclei), CD20 (B Cells), GL7 (Germinal Centers). Boxed section of LTR 20x images are the germinal center selected for higher magnification imaging shown below. Scale bars represent 300μM. (F) Tumor volume plot of rechallenge experiment. (Naïve n=3, MRX-2843 + CTX n=3, MRX-2843 + CTX + aPD1 n= 4). Two-way repeated measures ANOVA, p>0.001. (G) Summary schematic showing CXCL9+ Mo.Macs activate and recruit CD4 T cells, which then activate B cells to drive antitumor memory response. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

Article Snippet: The following primary antibodies and dilutions were used: CD4 (Abcam, ab183685, RRID:AB_2686917, 1:500), CD20 (CST, 70168,, 1:500), CD8a (CST, 98941, RRID:AB_2756376, 1:500), CD8a (eBioscience, 14–0081-82, RRID:AB_467087, 1:500), CD45R (BD Biosciences, 550286, RRID:AB_393581, 1:500), and Ly6C (Abcam, ab314120, 1:100) GL7 (Invitrogen, 53–5902-82, RRID:AB_2574228, 1:250).

Techniques: Immunohistochemistry, Staining, Expressing, Imaging

Journal: Molecular cancer therapeutics

Article Title: Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma

doi: 10.1158/1535-7163.MCT-26-0365

Figure Lengend Snippet: Fine needle aspirates of malignant lymph nodes were acquired from 8 dogs with cytologically confirmed lymphoma and screened for B cell (CD19, CD20, CD21) and T cell (CD5) markers by flow cytometry. (A) Representative plots from a nine-year-old male-castrated Bernese mountain dog (patient 5) and an 11-year-old female spayed German shepherd dog are displayed (patient 8). (B) Quantitative comparison of CD19, CD20, and CD21 expression across all screened dogs, with bars representing mean values. (Matched ranks of antigen expression were compared using Friedman’s test prior to Wilcoxon signed rank tests; ns: not significant).

Article Snippet: B cell antigen detection was performed using a custom-made APC-conjugated mouse anti-dog CD19 (clone 4E9, manufactured and conjugated to APC by Sino Biological), as well as a mouse anti-dog CD20 (clone 6C12, Cat no. dcd20-mab11-b, InvivoGen), which was purified using an Antibody Concentration and Clean-Up Kit (Cat no. ab102778, Abcam) prior to PE conjugation using a Lightning-Link Conjugation Kit (Cat no. ab102918, Abcam) in house.

Techniques: Flow Cytometry, Comparison, Expressing

Journal: Molecular cancer therapeutics

Article Title: Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma

doi: 10.1158/1535-7163.MCT-26-0365

Figure Lengend Snippet: (A) Four custom-designed tandem CAR (TCAR1–4) constructs that target canine CD19 and canine CD20 are depicted with cartoons showing the alternate arrangements of the CD19 and CD20 scFvs and the comprising vL and vH chains. (B) Histograms of TCAR expression with median fluorescent values in human Jurkat cells transduced with TCAR 4–1BBζ retroviral supernatant collected at 72 hours and 96 hours after transient transfection used for viral manufacture. (C) Representative flow plots of human Jurkat cells transduced with TCAR1-, 2-, and 4–4-1BBζ at an MOI of five were used to evaluate cell surface CAR expression by flow cytometry six days post-transduction. (D) Comparison of CAR surface expression in TCARs from three independent experiments with transductions quantified by flow cytometry at three and six days post-transduction. (E) Flow cytometric evaluation of CAR signaling using Jurkat NFAT GFP reporter cells transduced with TCAR1- and 2-CD28ζ, co-cultured for 16 hours with either no antigen present (GL-1), one antigen present (GL-1 cCD19, or GL-1 cCD20) or both antigens present (CLBL-1), one of two independent representative experiments is shown. (TCAR surface expression was compared using a 2-way ANOVA with Tukey multiple comparison’s test; ns: not-significant; FSC-H: forward scatter-height; NT: non-transduced).

Article Snippet: B cell antigen detection was performed using a custom-made APC-conjugated mouse anti-dog CD19 (clone 4E9, manufactured and conjugated to APC by Sino Biological), as well as a mouse anti-dog CD20 (clone 6C12, Cat no. dcd20-mab11-b, InvivoGen), which was purified using an Antibody Concentration and Clean-Up Kit (Cat no. ab102778, Abcam) prior to PE conjugation using a Lightning-Link Conjugation Kit (Cat no. ab102918, Abcam) in house.

Techniques: Transduction, Construct, Expressing, Retroviral, Transfection, Flow Cytometry, Comparison, Cell Culture

Journal: Molecular cancer therapeutics

Article Title: Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma

doi: 10.1158/1535-7163.MCT-26-0365

Figure Lengend Snippet: T cells transduced with TCAR1 from a 10-month-old female and a four-year-old male golden retriever were manufactured for functional analyses. (A) Flow cytometry plots following 96-hour co-cultures at a 5:1 effector-target ratio of NT or TCAR1 T cells with GFP-labeled GL-1, GL-1 cCD19, GL-1 cCD20, and CLBL-1 (CD19+CD20+) target cells to assess cytotoxicity. (B) Quantification of interferon-γ concentrations measured by ELISA in tissue culture supernatants after 48-hour cultures of NT and TCAR1 T cells alone or co-cultured at a 5:1 effector-target ratio with GFP-labeled GL-1 and CLBL-1 targets (dotted line represents the lower limit of detection for interferon-γ).

Article Snippet: B cell antigen detection was performed using a custom-made APC-conjugated mouse anti-dog CD19 (clone 4E9, manufactured and conjugated to APC by Sino Biological), as well as a mouse anti-dog CD20 (clone 6C12, Cat no. dcd20-mab11-b, InvivoGen), which was purified using an Antibody Concentration and Clean-Up Kit (Cat no. ab102778, Abcam) prior to PE conjugation using a Lightning-Link Conjugation Kit (Cat no. ab102918, Abcam) in house.

Techniques: Transduction, Functional Assay, Flow Cytometry, Labeling, Enzyme-linked Immunosorbent Assay, Cell Culture